Abstract. The optimization of large-scale screening procedures of pathological specimens by genomic, proteomic and metabolic methods has drastically increased the bioanalytical capability for swiftly identifying novel biomarkers of inherited disorders, such as neuromuscular diseases. X-linked muscular dystrophy represents the most frequently inherited muscle disease and is characterized by primary abnormalities in the membrane cytoskeletal protein dystrophin. Mass spectrometry-based proteomics has been widely employed for the systematic analysis of dystrophin-deficient muscle tissues, using patient samples and animal models of dystrophinopathy. Both, gel-based methods and label-free mass spectrometric techniques have been applied in comparative analyses and established a large number of altered proteins that are associated with muscle contraction, energy metabolism, ion homeostasis, cellular signaling, the cytoskeleton, the extracellular matrix and the cellular stress response. Although these new indicators of muscular dystrophy have increased our general understanding of the molecular pathogenesis of dystrophinopathy, their application as new diagnostic or prognostic biomarkers would require the undesirable usage of invasive methodology. Hence, to reduce the need for diagnostic muscle biopsy procedures, more recent efforts have focused on the proteomic screening of suitable body fluids, such as plasma, serum or urine, for the identification of changed concentration levels of muscle-derived peptides, protein fragments or intact proteins. The occurrence of muscular dystrophy-related protein species in biofluids will be extremely helpful for the future development of cost-effective and non-invasive diagnostic procedures. Novel biomarker signatures of dystrophinopathies will be indispensible for the swift evaluation of innovative therapeutic approaches, such as exon skipping, codon-read-through or stem cell therapy.
INTRODUCTION
Over the last decade, skeletal muscle proteomics has developed into a new discipline within the field of basic and applied myology [1] . Proteomics has been applied to a wide range of muscle-related topics, in the determination of key post-translational modifications in muscle proteins such as glycosylation [23] , phosphorylation [24] , carbonylation [25] , nitrosylation [26] and acetylation [27] . The systematic proteomic screening of skeletal muscle pathologies has included the analysis of patient biopsy material and muscle preparations from established animal models of muscle diseases, covering neuromuscular abnormalities such as drug-related muscle damage [28] , toxin-associated muscle alterations [29] , denervationinduced muscular atrophy [30, 31] , motor neuron diseases [32] [33] [34] , limb-girdle muscular dystrophy [35] , hyper-excitability related myotonia [36] , insulin resistance and diabetes-associated muscle weakness [37] [38] [39] , obesity-related changes in muscle tissues [40, 41] , inclusion body myositis [42] , autoimmune myasthenia gravis [43] , dysferlinopathy [44] , myofibrillar myopathies [45] [46] [47] , and post-mortem changes in skeletal muscle [48] . In addition, the downstream effects of dystrophin deficiency were studied by various proteomic approaches [49] .
Building on these extensive sources of information, this review focuses specifically on the mass spectrometry-based identification of novel proteomic biomarkers of dystrophinopathies and their potential as future diagnostic tools. Proteins are listed by functional families including internal muscle-associated proteins involved in the contraction-relaxation cycle, glycolysis, mitochondrial metabolism, cellular signaling, ion handling, the extracellular matrix, the cytoskeleton and the cellular stress response, as well as muscle-derived peptides, protein fragments and intact proteins that are leaked or released into body fluids such as plasma, serum or urine. The importance of proteomic biomarkers for the future development of superior diagnostic procedures is discussed.
PROFILING OF MUSCLE-ASSOCIATED AND MUSCLE-DERIVED PROTEINS

Skeletal muscle proteomics
High-resolution gel electrophoresis and/or liquid chromatography have been routinely used to separate various protein constellations from skeletal muscle specimens. The identification of muscle proteins by mass spectrometry has been carried out with both labelling approaches and label-free analyses [50] . The systematic cataloguing of the highly dynamic skeletal muscle proteome has established a list of several thousand proteins and isoforms that are present in greatly varying concentration ranges in voluntary contractile tissues [4, [51] [52] [53] . Organelle proteomics has established the subproteome of distinct muscle fractions [54] , such as the sarcolemma, the sarcoplasmic reticulum and mitochondria [55] [56] [57] . Recently, several extensive reviews have summarised and critically examined the impact of large-scale proteomic approaches for our general understanding of human muscle biology [1] , skeletal muscle differentiation and aging [58] , muscle plasticity and fibre heterogeneity [59] and exercise-induced fibre adaptations [60, 61] , as well as the molecular composition of the contractile apparatus [62] and the dystrophin-glycoprotein complex [63] . In addition, the technical challenges and emerging techniques in muscle proteomics [50] and key issues in proteomic biomarker discovery in the field of neuromuscular disorders [64] have been reviewed. These articles have outlined in detail the most commonly employed methods for protein separation and protein identification used in muscle tissue proteomics and also contain detailed listings of proteomic investigations with relevance to inherited muscle diseases. Thus, for detailed background information on proteomic strategies as specifically applied to skeletal muscle biology, we would like to refer to the above listed publications.
Skeletal muscle proteome complexity
Various technical limitations and biological issues complicate the proteomic screening of crude muscle extracts for the swift identification of new diseasespecific biomarkers. These issues are encountered during almost all global analyses of protein constellations in complex tissues and organs [65] [66] [67] . On the cellular level, skeletal muscles are highly diverse in their composition and consist of the main contractile fibres, which exist in a wide range of multinucleated slow-oxidative, fast-oxidative-glycolytic, fast-glycolytic or hybrid cell types [68] , in conjunction with satellite cell pools underneath the basal lamina, distinct layers of connective tissue comprising of the endomysium, perimysium and epimysium, a complex network of capillaries, and motor neurons and their specialized connection sites at the neuromuscular junction [64] . On the subcellular level, various muscle proteins display a multi-compartmental localization and a considerable dynamic in their cellular movements and interaction patterns [54] . On the molecular level, muscle tissues display a highly diverse number of protein families with an exceptionally large variety of isoforms, which exist in a wide dynamic range of expression levels [4, [51] [52] [53] .
Technical limitations and biological issues in muscle proteomics
In the case of technically straightforward cataloguing studies of the muscle proteome [51, 53] , the exceptional sensitivity and analytical capability of modern mass spectrometers enables the comprehensive evaluation of heterogeneous tissue extracts for the efficient identification of specific isoforms of even low copy number proteins [69] . In contrast to shotgun proteomics, the extensive molecular and cellular heterogeneity in contractile tissues presents a serious analytical challenge in comparative pathobiochemical studies. Muscle diseases are often related to complex changes. For example, the progressive nature of X-linked muscular dystrophy is associated with alterations in the interstitial volume, a drastic increase in connective tissue, elevated endomysial fat layers and the infiltration of damaged fibres by cells that provide the natural immune response. These additional changes in an already highly heterogeneous cell mixture certainly complicate the interpretation of studies using tissue proteomics. In addition, the preferential susceptibility of certain fibre types to necrosis may result in complex and unpredictable fiber type transitions during different disease stages [70] . A potential preparative artifact is the occurrence of abundant blood-borne proteins in skeletal muscle homogenates, such as hemoglobin subunits, which depends heavily on the appropriate usage of tissue perfusion prior to protein extraction and large-scale protein separation.
These technical problems and biological matters may genuinely complicate the proper interpretation of findings from comparative tissue proteomics and make it difficult to distinguish between protein changes due to general tissue damage, adaptive processes during regeneration cycles and highly disease-specific alterations downstream from the primary genetic insult. In the case of analyzing needle biopsy material from Duchenne patients, an additional issue is the fact that a tissue sample from a single biopsy might not be fully representative of the overall pathology in whole muscle [71] . Usually a wide heterogeneity of muscle defects exists within the neuromuscular system in the same patient, limiting the validity of biomedical data received from a single biopsy. This may seriously complicate the extrapolation of proteomic biomarker findings in the case of monitoring therapeutic interventions.
Serum markers of muscle damage
In the past, an array of muscle-derived protein markers has been used for diagnostic purposes. However, many of these biomarkers do not exhibit a high degree of specificity and/or consistent concentration changes in the acute or chronic disease stage, which restricts their usefulness for accurate diagnosis, proper monitoring of dystrophic progression and clinical outcome measures. General serum markers of muscle injury or cellular damage include creatine kinase, carbonic anhydrase isoform CA3, troponin subunit TnI, myosin light chain MLC1, fatty acid binding protein FABP3, myoglobin, aspartate amino transferase, alanine amino transferase, hydroxybutyrate dehydrogenase, adenylate kinase, aldolase, pyruvate kinase, enolase and lactate dehydrogenase [64, 72, 73] . The graph in Fig. 1 shows the normal range of human plasma-associated proteins. It has been estimated that the concentration range of plasma proteins ranges from ρg/ml-values at the low end to mg/ml-values at the high end [74] . General markers of tissue leakage, including serum proteins indicative of muscle damage, are marked in Fig. 2 . Their elevated appearance in serum or plasma samples is a general sign of impaired fibre integrity. It is important to note that plasma and serum biochemistry depends considerably on the reproducibility of the sampling method, which is especially crucial in the case of comparative studies.
Proteomic complexity of body fluids
Although plasma, serum, urine, saliva and other biofluids are ideal sources for the swift discovery of new disease markers, as well as present the preferred minimally invasive specimens to test normal individuals, at-risk groups and patients, the potential problem with the wide dynamic protein expression range is a serious analytical issue with most body fluids [75] . This is especially apparent in the case of the serum and plasma proteome and neither liquid chromatography nor high-resolution gel electrophoretic methods are capable of separating the entire spectrum of proteins within a complex biological mixture [76] . The extremely wide dynamic range of protein concentrations present in human plasma, as outlined in Figs. 1 and 2, represents a major obstacle. Low-abundance proteins such as many cytokines are present at a concentration in the ρg/ml range, while albumin is present at concentrations in the region of 30-45 mg/ml [77] . This huge difference in concentrations represents at least twelve orders of magnitude with the potential to be even greater as some biomolecules are present at concentrations lower than many cytokines [78] . In addition, many low-abundance components bind to highly abundant proteins, such as albumin, thereby masking their presence. This adds a layer of complexity to their detection and quantification, which should be properly considered when using prefractionation approaches, such as immuno-depletion protocols [79, 80] . A major advantage of body fluids is the ability to take serial samples to monitor disease burden or response to therapeutic agents based on altering levels of suitable protein biomarkers. Biological material assayed for biomarker discovery can also originate from proximal fluids, which are defined as biofluids in close or direct contact with the site of disease. In contrast to serum or plasma, it is very likely that these biomarker-rich reservoirs will facilitate the discovery of disease-related biomarkers. Depending on the specific disorder, suitable proximal biofluids may include cerebrospinal fluid, broncho-alveolar lavage fluid, saliva, urine, cerumen, tears and various gastrointestinal fluids such as bile, pancreatic juice and gastric juice [81] [82] [83] . For example, levels of HIP/PAP-I (hepatocarcinoma-intestine-pancreas/pancreatitisassociated-protein-I) were found to be approximately 1000-fold higher in pancreatic juice as compared to serum from patients diagnosed with pancreatic adenocarcinoma [84] . However, mirroring difficulties associated with investigating serum or plasma, proximal biofluids also have a wide dynamic range of protein abundance levels, with cerebrospinal fluid having up to twelve orders of magnitude [85] . To help assist the detection of low-abundance and disease-specific biomarkers, a number of fractionation and enrichment strategies are available to provide a standardised method to process biofluid specimens including immuno-depletion, combinatorial hexapeptide ligand libraries and nanoparticle harvesting approaches.
Protein enrichment strategies in biofluid proteomics
The extremely high concentration of a few proteins in serum or plasma seriously interferes with the identification of low copy number proteins. Therefore the high concentration of proteins such as albumin, transferrin, fibrinogen, haptoglobin, antitrypsin, transthyretin and various immunoglobulins Fig. 2 . Graphical presentation of the dynamic range of low-abundance proteins in the human plasma proteome. Shown is the average concentration range of general plasma-associated protein markers of tissue leakage and low-abundance plasma proteins. The average, normal abundance of typical muscle-derived proteins, such as aldolase, myoglobin, carbonic anhydrase, fatty acid binding protein, creatine kinase and troponin subunits, is marked. Drastically increased levels of these proteins in serum or plasma samples are indicative of general muscle damage and disintegration of fibre integrity.
necessitates often pre-fractionation steps in order to be able to detect low-abundance proteins in serum samples [79, 80, 86] . Immuno-depletion of biofluid specimens for the removal of highly abundant proteins is a practical and reproducible solution. Typically, selected proteins are removed using immuno-depletion columns containing antibodies against the hyperabundant proteins such as albumin, IgG, IgA, IgM, fibrinogen, transferrin and haptoglobin. Removal of high-abundance proteins and consequently the establishment of an enriched pool of low-abundance proteins enable improved resolution and a compressed dynamic range for biomarker discovery experiments using label-free shotgun profiling with LC-MS/MS analysis, as well as two-dimensional gel-based techniques. Immuno-depletion of clinical samples has facilitated the discovery of many candidate biomarkers and is now routinely used as a robust strategy to help overcome some of the problems associated with dynamic range [87, 88] . However, immunodepletion is not without some drawbacks. One of the most significant problems is the co-depletion of many low-abundance proteins during the processing of samples as a consequence of non-specific binding to antibodies or through their interactions with highly abundant proteins such as albumin. This is known as the carrier-and-cargo effect. Importantly, Yadav et al. [89] identified 101 proteins with high confidence in the bound fractions from three plasma samples depleted using each of the three multi-affinity removal system MARS cartridges, e.g. Hu-6, Hu-14 and Proteoprep 20. Such results strongly suggest it may be prudent to analyse both high and low abundant fractions to maximize the overall detection rate and quantification of as many plasma-associated proteins as possible.
Hexapeptide libraries, such as ProteoMiner™ protein enrichment technology, can substantially increase the sensitivity of shotgun proteomic analyses of complex biofluid samples [90, 91] . Dynamic range compression is a result of high abundant proteins quickly saturating their specific ligands while mediumand low-abundant proteins continue to bind to their ligands, resulting in a significant dilution of highabundance proteins while low-abundance molecules are concentrated. The ProteoMiner™ technology is based on a combinatorial library of hexapeptides bound to a chromatographic support. The vast ligand diversity based on 64 million unique beads generated offers in theory a ligand for every protein present in the starting material. Currently, hexapeptide libraries have been mostly used to increase proteomic detection in biofluid samples such as serum and plasma, although Candiano and co-workers [92] reported that at least 3,300 protein spots could be visualized in a two-dimensional gel map from urine using a modified ProteoMiner™ enrichment approach.
Degradation of protein biomarkers can occur immediately following the collection of biofluids as a result of endogenous or exogenous proteinase activity. To overcome this issue, nanoparticles or nanotraps are able to concentrate and protect sensitive protein populations. This approach uses a combination of size exclusion and affinity capture methodology to enrich for low-molecular-mass proteins [93, 94] . Both the size exclusion and affinity capture components of the nanotraps are adjustable, therefore allowing researchers to screen their clinical samples using a panel of molecular baits to capture many disease-related proteins present in the starting material. The suitability of this technology is exemplified by a recent study with polynanoparticles that reliably measured a low-abundance protein analyte, the human growth hormone HGH in urine [95] . This demonstrates how the match of specific bait chemistry can be exploited to capture a certain analyte. Traditional fractionation techniques are also very effective at helping to increase the coverage of biofluid proteomes, including chromatography approaches such as cation exchange, anion exchange, one-dimensional polyacrylamide gel electrophoresis and ZOOM ® isoelectric focusing pre-fractionation procedures [96] [97] [98] . Indeed, combinations of two or more fractionation techniques have been employed by some groups to generate many fractions, helping to reduce sample complexity and enhance the ability to identify low concentration biomolecules [99, 100] .
PROTEOMIC ANALYSIS OF MUSCULAR DYSTROPHY
Proteomic profiling of dystrophin and dystrophic muscle tissues
The primary deficiency in the membrane cytoskeletal protein dystrophin is the underlying cause of X-linked muscular dystrophy [101] . In normal muscle, dystrophin forms a large complex with several sarcolemmal proteins, including dystroglycans, sarcoglycans, dystrobrevins, syntrophins and sarcospan [102] [103] [104] . Figure 3 summarizes the proteins linked to dystrophin at the interface between the subsarcolemmal cytoskeleton and the basal lamina and also outlines the relationship of the dystrophin-glycoprotein complex to other surface networks based on integrins and spectrin located in the plasmalemma, as well as utrophin at the neuromuscular junction [105, 106] . In addition, major contractile and regulatory proteins of the actomyosin apparatus, elements of intermediate filaments and the lamin-associated nuclear membrane complex are listed. Since direct or indirect connections exist between the various extracellular, sarcolemmal, cytoskeletal and contractile protein families, the absence of dystrophin and severe reduction in dystrophin-associated glycoproteins may also affect other components of the cytoskeleton, the contractile apparatus or the extracellular matrix [107, 108] . Thus, the leakage or release of proteins, protein fragments or peptides belonging to these cytoskeletal or contractile protein networks may be exploitable as muscle-derived biomarkers of muscular dystrophy. A large number of candidate proteins that are potentially altered in dystrophinopathies are listed in Fig. 3 .
Mass spectrometry-based proteomics has been widely applied to studying isolated components of the dystrophin-glycoprotein complex [109] [110] [111] [112] and dystrophic muscle samples and biofluids. This has included established animal models of muscular dystrophy [113] [114] [115] [116] [117] and patient specimens. Global changes in muscle-associated proteins were determined using serum samples from the mdx mouse [118, 119] and Duchenne patients [120] [121] [122] , the secretome of mdx myotubes [123] , Duchenne muscle biopsies [124] , the cytosolic mdx muscle fraction [125, 126] , microsomes from mdx leg muscle [127] , crude mdx hind limb muscle extracts [128] , individual mdx leg muscles including gastrocnemius, tibialis anterior, extensor digitorum longus, soleus, flexor digitorum brevis and interosseus muscles [129] [130] [131] [132] , mildly affected mdx extraocular muscles [133, 134] , the severely dystrophic mdx diaphragm [134] [135] [136] [137] [138] [139] , the mdx heart [140] [141] [142] and skeletal muscle extracts from the grmd dog [143] .
Although the primary insult causing a diseasealtered state in muscular dystrophy is the loss in the dystrophin isoform Dp427 [101] , assaying fulllength dystrophin is not necessarily the most suitable biomarker test. The reason for this is the fact that interface between the sub-sarcolemmal actin cytoskeleton and the basal lamina and the utrophin-glycoprotein complex at the neuromuscular junction, as well as the plasmalemmal networks based on integrins and spectrin complexes. Major proteins associated with the contractile apparatus, the cytoskeleton and the extracellular matrix, which indirectly link to dystrophin, are presented in separate panels. Biomarker signature of dystrophinopathies! Fig. 4 . Summary of the routine proteomic workflow for the swift identification of new dystrophinopathy-related biomarker candidates. Suitable biomarkers may be present in muscle fibres, muscle-associated but non-contractile tissues, non-muscle tissues or biofluids.
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the primary abnormality in this essential membrane cytoskeletal protein may trigger irreversible changes in certain pathways and cellular signaling mechanisms during the impaired development of dystrophindeficient fibres. Therefore, the successful restoration of dystrophin in muscle fibres may not counter-act all dystrophy-related abnormalities. This might include the pathobiochemical consequences of progressive fibre degeneration, extensive fibrotic scaring and the extensive fatty tissue accumulation in dystrophic muscles. However, even if dystrophin substitution by pharmacological interventions or gene therapy does not reverse all secondary changes [144] [145] [146] , alterations in the concentration of the Dp427 isoform could be employed as a pharmacodynamic biomarker that documents the successful reestablishment of the primary abnormality in dystrophinopathy [147] . Additional tests are then needed to evaluate the clinical value of therapeutic interventions, such as motor assessment, general physical examinations, histological tests and magnetic resonance imaging, as well as routine protein marker assays of downstream effects. This makes the identification of novel and reliable protein biomarkers an urgent task of muscle proteomics and warrants detailed investigations into proteome-wide changes in muscular dystrophy. Figure 4 summarizes the proteomic workflow for the identification of novel dystrophinopathy-specific biomarker candidates present in dystrophin-deficient muscle fibres, non-muscle tissues or suitable body fluids.
Contractile and regulatory proteins of the actomyosin apparatus
The proteomic screening of dystrophic muscle samples has revealed an altered concentration of the main contractile and regulatory proteins of the actomyosin apparatus. This includes myosin heavy chains, myosin light chains, troponin, tropomyosin and actin, as well as auxiliary proteins such as myosin binding protein, myozenin, myomesin and ␣-actinin [126, 129-132, 134-139, 143] . The gel electrophoretic analysis of the cytosolic fraction of mdx hind limb muscle revealed changes in myosin light chain MLC2 and tropomyosin [126] , in conjunction with the drastic decrease in adenylate kinase isoform AK1 [125] . While moderate decreases in ␣-actinin, fast myosin binding protein MBP-C, ␣-actin and myosin heavy chains MHC IIx and MHCIIb were described to occur during the acute phase of dystrophin-deficiency in mdx gastrocnemius muscle as determined by 2D-DIGE analysis [129] , SILAC (stable isotope labeling by amino acids in cell culture) proteomics showed slight decreases in various myosin heavy chains, ␣-actin and ␣/␤-tropomyosin [132] . Several other leg muscles exhibiting segmental necrosis were studied at a more advanced stage of muscular dystrophy. Proteomics revealed alterations in troponin TnC, myosin binding protein MBP-C and myosin light chains MCL2 and MLC3 in soleus muscle, troponin TnT and myosin heavy chain in extensor digitorum longus muscle, troponin TnI and ␣/␤-tropomyosin in flexor digitorum brevis muscle and troponin TnI in interosseus muscle [131] , as well as decreased ␣-tropomyosin levels in aged mdx tibialis anterior muscle [130] . Moderate differential expression levels were established for tropomyosin, myosin light chains MLC1, MLC2 and MLC3, various myosin heavy chains, myosin binding protein MBP-H, myotilin and myomesin in the dystrophic grmd dog model of Duchenne muscular dystrophy [143] .
The severely dystrophic mdx diaphragm showed changes in various myosin heavy and light chains, actin, troponins and actinin [134, [136] [137] [138] . Aged mdx diaphragm muscle, which is characterized by a drastic increase in collagen [138] , exhibited differential expression patterns of myosin light chains, tropomyosin, troponins, actin and nebulin [139] . Interestingly, the myosin light chain isoform MLC1 was identified in secreted LAMP1-associated vesicles [123] , as described in below section on released biomarkers in biofluids. In contrast to relatively moderate and differential effects of dystrophin deficiency on skeletal muscles, the cardiac proteome showed unilateral decreases of many contractile proteins in muscular dystrophy-associated cardiomyopathy [141, 142] . The reduced abundance is especially striking for cardiac myosin light chain MLC2, as revealed by fluorescence 2D-DIGE analysis [141] . However, despite the many observed proteomic changes described in this section, it is currently difficult to establish alterations in a specific contractile protein as a suitable biomarker assay for dystrophinopathies. The high abundance and dynamic expression range of myosins and other contractile proteins complicate the development of sensitive tests for potential internal muscle markers. Probably, a panel of proteins belonging to the actomyosin complex and its auxiliary structures would be more appropriate for evaluating complex dystrophyrelated changes in the contractile apparatus.
Enzymes of energy metabolism
The continuous provision of energy is essential for muscular activity making both the coordination and maintenance of anaerobic and aerobic bioenergetic pathways critical issues in contractile fibres [148, 149] . Glycolytic enzymes and the mitochondrial subproteome make up a considerable part of the muscle protein constellation [4, [51] [52] [53] . Mitochondrial proteins account for approximately 20% of the skeletal muscle proteome [51] and the 10 glycolytic enzymes represent the most abundant proteins of the diffusible muscle fraction [150] . In general, muscle wasting is closely associated with alterations in bioenergetic provision and reflected by a variety of changes in glycolysis [151] and oxidative phosphorylation [152] . In dystrophinopathy, an impaired mitochondrial metabolism appears to be based on the pathophysiological uncoupling of oxidative phosphorylation and a considerable reduction in maximal ATP synthesis capacity [153] . This mitochondrial inefficiency and resulting decreased intramuscular ATP levels might be directly linked to a disrupted sub-sarcolemmal localization of mitochondria due to dystrophin deficiency in the actin membrane cytoskeleton [154] .
Besides alterations in the localization and regulation of bioenergetic organelles and shifts in the concentration and/or isoform expression levels of metabolic enzymes, the abundance and availability of metabolite transporters and binding proteins may represent limiting factors of bioenergetic pathways. Therefore the transportation of glucose, amino acids, nucleotides, fatty acids and oxygen on the one hand and the efficient removal of waste products and CO 2 on the other hand play an essential role in muscle metabolism [148] . Dystrophy-related changes in metabolite transportation or removal have been reported to occur on the level of myoglobin, fatty acid binding protein FABP3 and carbonic anhydrase CA3. While aged mdx diaphragm muscle has drastically lowered levels of fatty acid binding protein and myoglobin [139] , the aged mdx tibialis anterior muscle showed high concentrations of carbonic anhydrase [130] . This indicates impaired utilization of fatty acids for oxidative metabolism in severely dystrophic fibres and apparently an additional need to remove excess CO 2 from dystrophic muscles. Muscle proteins involved in lipid metabolism, mitochondrial bioenergetics, glycogen storage, glycol-ysis, gluconeogenesis and nucleotide metabolism have shown a generally perturbed expression pattern, but no clear unilateral shifts between anaerobic and aerobic metabolism are evident. However, since many muscle proteins are probably multi-functional, it is difficult to interpret individual changes within bioenergetic pathways and their implications for overall metabolic changes during muscle wasting.
Mitochondrial and glycolytic enzymes were shown to display both increased and decreased concentration levels in dystrophic muscles. Interestingly, the enzyme aldolase has been shown to be reduced in almost all subtypes of skeletal muscles in dystrophic mouse or dog models of Duchenne muscular dystrophy [129, 131, 134, 136, 137, 143] . During glycolysis, an aldolase-mediated reversible reaction brakes down fructose-1,6-biphosphate into glyceraldehyde-3-phosphate and dihydroxyacetone phosphate [151] . The gluconeogenic enzyme fructose-1,6-biphosphatase appears to form complexes with aldolase in conjunction with ␣-actinin on both sides of the Z-line of muscle fibres [155] . This physical linkage between key enzymes of glycolysis and gluconeogenesis probably enables efficient substrate channeling between these metabolic enzymes [156] . The decrease in aldolase in dystrophic muscle was reversed after experimental exon-skipping therapy, suggesting this glycolytic enzyme as a potential internal muscle marker of metabolic adaptations in muscular dystrophy [137] . The mitochondrial enzyme isocitrate dehydrogenase exhibits also a significantly reduced expression in dystrophic mdx diaphragm and gastrocnemius muscle [132, 136] and exon-skipping intervention counter-acts the loss in this critical protein of the citric acid cycle [137] . Thus, both key enzymes of the sarcoplasmic fraction and the mitochondrial matrix may be useful as pharmacodynamic biomarkers in future gene therapy trials.
Numerous proteomic studies have convincingly shown alterations in the nucleotide metabolism of dystrophic muscles. The AK1 isoform of adenylate kinase and mitochondrial creatine kinase are reduced in dystrophic skeletal and cardiac muscles [125, 126, 135-137, 139, 141] . These proteomic findings were verified by immunoblot analysis [125, 137] . Hence, muscle nucleotide metabolism that involves the enzymatic activities of creatine kinase and adenylate kinase seems to be altered in dystrophin-deficient fibres. Experimental exon skipping therapy reversed the reduction in both enzymes [137] , establishing adenylate kinase AK1 and the mitochondrial form of creatine kinase as potential muscle-associated biomarker candidates for the evaluation of therapy and disease monitoring of progressive skeletal muscle wasting and cardiomyopathic complications associated with X-linked muscular dystrophy. In contrast to reduced levels of enzymes of nucleotide metabolism, proteins involved in iron metabolism were shown to be increased in muscular dystrophy.
The comparative proteomic analysis of the contractile protein-depleted microsomal fraction from normal versus dystrophic skeletal muscle revealed an increase in ferritin and transferrin [127] . A moderate elevation in transferrin was also show in the acute phase of dystrophin deficiency of young mdx muscle [129] and the aging mdx heart exhibited drastic increases in ironregulatory proteins [142] . Ferritin is a ubiquitous intracellular iron-binding protein involved in iron detoxification and iron reserve by sequestering and releasing iron in a highly regulated way. Transferrin serves as a circulating protein, which delivers iron to tissue proteins [157] . The elevated levels of iron-binding proteins indicate disturbed iron homeostasis in dystrophindeficient fibres and might counter-act a potential iron overload in muscular dystrophy. The fact that all mammalian cells require proper regulation of iron levels for metabolic maintenance makes the concentration of transferrin and ferritin crucial indicators of potential adaptations or impairments in iron absorption and usage [158] . This might make iron-binding proteins also suitable metabolic biomarker candidates for evaluating the status of X-linked muscular dystrophy.
Proteins involved in excitation-contraction coupling and ion homeostasis
Excitation-contraction uncoupling and abnormal Ca 2+ -fluxes through the dystrophin-deficient plasmalemma, as well as impaired Ca 2+ -shuttling and lowered Ca 2+ -buffering capacities in the cytosol and the lumen of the sarcoplasmic reticulum are major contributory factors of secondary alterations in muscular dystrophy [159] . The calcium hypothesis of muscular dystrophy assumes that abnormal calcium homeostasis in mechanically stressed muscle cells plays a key role in contractile weakness. Biochemical, physiological and proteomic studies have confirmed unbalanced ion cycling through the sarcolemma of dystrophic fibres and an impaired Ca 2+ -buffering capacity of the terminal cisternae region of the sarcoplasmic reticulum [128, 134, 135, 139, [160] [161] [162] [163] [164] . Abnormal Ca 2+ -handling may contribute in a major fashion to an enhanced level of muscle protein degradation [165, 166] . The normal movement of Ca 2+ -ions, which present one of the most critical second messenger molecules in skeletal muscle, is maintained under precise temporal and spatial control by the highly regulated interactions between Ca 2+ -channels, Ca 2+ -shuttle proteins, Ca 2+ -binding proteins, Ca 2+ -release units, ion exchangers, Ca 2+ -pumping ATPases and voltage-sensing receptors [167] . Disturbances of this complex physiological system, which indirectly regulates many metabolic and signaling mechanisms, may result in severe fibre degeneration.
Dysregulation of excitation-contraction coupling and muscle relaxation due to an anomalous intracellular accumulation of Ca 2+ -ions and resulting chronic Ca 2+ -overload is believed to cause disintegration of sarcolemmal integrity by activating Ca 2+ -dependent proteolytic processes [159, 166] . Micro-rupturing of the dystrophin-deficient sarcolemma triggers a Ca 2+ -related membrane re-sealing process that in turn initiates the introduction of sarcolemmal patches containing Ca 2+ -leak channels that provide an increased influx of Ca 2+ -ions into the sarcoplasm of dystrophic fibres [164] . The comparative biochemical and proteomic profiling of dystrophic muscle versus wild type has shown decreased levels of the Ca 2+ -binding proteins parvalbumin, regucalcin, calsequestrin, calsequestrin-like proteins and sarcalumenin [128, 134, 135, 139, 162, 163] . The proteomic analysis of experimental exon skipping clearly showed a reversal of the reduced levels of fast calsequestrin following anti-sense treatment of the mdx diaphragm muscle [137] . This makes changes in the concentration of the cytosolic Ca 2+ -binding proteins parvalbumin [139] and regucalcin [135] , the luminal Ca 2+ -shuttle protein sarcalumenin [162] , the calsequestrin-like proteins of high molecular mass named CLP1 to CLP5 [163] and the fast 63 kDa isoform of the luminal Ca 2+ -binding protein calsequestrin [128, 134, 139] suitable biomarker candidates for the monitoring of changes in Ca 2+ -handling in dystrophic skeletal muscle.
Cytoskeletal and extracellular matrix proteins
The dystrophin-glycoprotein complex links the outside of the muscle fibre via the trans-sarcolemmal dystroglycan sub-complex to the internal actin cytoskeleton [104, 106, 108] . In both, mdx mouse muscle and skeletal muscle biopsies from Duchenne patients, the deficiency in dystrophin isoform Dp427 results in a drastic reduction in all dystrophinassociated glycoproteins [102, 168, 169] . However, the extracellular matrix protein laminin is not affected by the primary abnormality in dystrophin [139] and the cytoskeletal protein spectrin is also not altered in its concentration in muscular dystrophy [168, 169] . This makes laminin and spectrin suitable marker proteins for equal loading controls in comparative biochemical studies of dystrophic versus wild type skeletal muscle specimens. However, in the dystrophic heart, laminin was shown to be drastically reduced. Label-free mass spectrometry revealed lower levels of laminin and nidogen in the aged mdx heart and these findings were confirmed by immunoblot analysis [142] . The dystrophic heart exhibits a variety of differences in its secondary abnormalities as compared to dystrophindeficient skeletal muscle tissues [170] , and possibly the differing subcellular localization of the cardiac dystrophin complex might play a role in the drastic loss of laminin. In the heart, dystrophin and its associated glycoproteins are located in both the sarcolemma and the transverse tubules, while the skeletal muscle complex is restricted to the sarcolemma and junctional folds of the neuromuscular junction region. Thus, the measurement of laminin levels might be a useful indicator for the differential evaluation of muscular dystrophy versus dystrophy-related cardiomyopathy.
Numerous proteomic studies indicate that the concentration of the extracellular matrix protein collagen and the cytoskeletal proteins vimentin, desmin and tubulin are increased in dystrophinopathies [129, 132, 134, 136, 138, 139] . Proteomic profiling and comparative immunoblotting of the fibrotic status of the aged mdx diaphragm revealed a drastic increase of the extracellular matrix proteins collagen and dermatopontin [138] . Although the natural aging process of the musculature is associated with higher collagen levels [171] , senescent fibres lacking dystrophin exhibit a several times elevated level of collagen [138] . The increased density of the intermediate filament proteins vinculin and desmin and the main microtubule-forming component tubulin indicate compensatory mechanisms to counter-act the structural weakness of the cytoskeletal network in dystrophic fibres [129, 132, 136] . Interestingly, desmin, vimentin and actin form complexes with ␣B-crystallin-like chaperones in contractile tissues during prolonged periods of cellular stress [172] . Small heat shock proteins appear to be directly involved in the modulation of intermediate filament assembly. Although vimentin appears to be only transiently expressed during myotube maturation [173] , the concomitant increase in desmin and the molecular chaperone cvHSP, as discussed in more detail below, strongly suggests a stabilizing function through increased levels of this cytoskeletal element. The additional support of microtubules and interme-diate filaments might at least partially substitute for the loss of dystrophin in the impaired actin membrane cytoskeleton.
In addition, the dystrophic mdx heart is characterized by a reduction in the protein lamin of the nuclear envelope complex [142] . The reduced presence of lamin may drastically weaken the linkage between the lamin network and its associated proteins nesprin, SUN1, SUN2 and plectin at the interface between muscle nuclei and the cytoskeleton [174] . With respect to biomarker discovery for dystrophinopathies, the proteomic identification of altered concentration levels in distinct cytoskeletal proteins suggests desmin, vimentin, tubulin and lamin as potential candidates for developing diagnostic tests for the differential analysis of muscular dystrophy.
Molecular chaperones
During both normal contractile activities and pathological conditions, considerable cellular stress is exerted on the neuromuscular system. Therefore, the continued preservation of muscle proteostasis is at the core of protecting and adapting contractile tissues. This includes on the one hand the maintenance of correct protein folding, efficient protein transportation and appropriate protein complex arrangements to provide the structural basis for diverse muscle functions, and on the other hand the effective removal of misfolded proteins during extended periods of pathological adaptations or cellular stress [175] . In skeletal muscle, various molecular chaperones are involved in protein stabilization by supporting the correct functional fold of peptide domains and eliminate non-functional protein aggregations [176] . Besides protein disulfide isomerase, peptidyl prolyl isomerase, calreticulin and calnexin, a large number of heat shock proteins (HSP) are involved in the cellular stress response [177] . Muscle-specific expression was shown for low-molecular mass HSP molecules (HSPB), such as the ␣B-crystallin like cardiovascular HSP (HSPB7, cvHSP) [178] . HSPs with higher molecular masses are represented by HSP40 (DNAJ), HSP60 (HSPD), HSP70 (HSPA) and its co-chaperones, HSP90 (HSPC) and HSP110 [176] .
Pathobiochemical studies of dystrophic muscles have demonstrated an elevated concentration of HSP65 and HSP72 in hyper-contracted fibres from Duchenne patients [179] and increases in HSP70 and HSP90 in tissue extracts from Duchenne muscle samples [180] . The experimental iron deprivation of mdx muscle triggered a selective decrease in the over-expression of HSP70, suggesting that the iron-associated generation of hydroxyl radicals may be linked to the severity of muscle necrosis and possibly modify the cellular stress response in dystrophinopathies [181] . The crucial role of HSPs in the molecular pathogenesis of muscular dystrophy is illustrated by the fact that exposure to the experimental drug BGP-15, which represents a pharmacological inducer of HSP72, clearly improves muscle structure and contractile strength in dystrophic mdx and dko mice [182] . Since the up-regulation of HSP72 acts via the functional restoration of the sarcoplasmic reticulum Ca 2+ -ATPase [182] and transgenic overexpression of this enzyme has been shown to attenuate dystrophic features in mdx fibres [183] , most likely the restoration of a low cytosolic Ca 2+ -concentration and reversal of excess sarcolemmal Ca 2+ -influx is crucial in preventing muscle degeneration. Thus, molecular chaperones like HSP72 are essential factors for the cyto-protection of stressed fibres [182] .
Proteomics has identified drastic changes in the expression of cvHSP (HSPB7), ␣BC (HSPB5), HSP70 (HSPA) and HSP90 (HSPC) in dystrophic muscles [126, 127, 129, 134, 136, 139] , which qualifies some molecular chaperones as potential biomarkers of skeletal muscle degeneration [184] . In stressed muscle fibres, a highly complex system of protective pathways is concerned with the continuous maintenance of contractile and metabolic protein functions. Muscle protein protection and preservation involves the general support of protein homeostasis, the facilitation of three-dimensional protein folding into the native molecular state and the protection of proteome integrity. Therefore, progressive muscular dystrophy is associated with drastic changes in chaperoning molecules. Especially the class of small and relatively muscle-specific chaperones might be useful for diagnostic and prognostic purposes. It is encouraging that the molecular chaperone cvHsp has already been successfully employed for the biochemical evaluation of experimental exon skipping therapy [137] . A potential disadvantage of heat shock proteins is their intramuscular location, but the proteomic profiling of the secretome of mdx myotubes suggests that the released chaperones HSP-5, HSP-8 and HSP90 may be suitable biomarker candidates in biofluids [123] .
Biotransformation enzymes
The continued detoxification of potentially harmful substances, the biotransformation of xenobiotics and the anti-oxidant protection are natural defense mechanisms of muscle fibres and involve a variety of enzyme systems. It is therefore not surprising that free radical production, oxidative stress and impaired biotransformation has been suggested to play an important role in the molecular pathogenesis of dystrophinopathies [185] [186] [187] . As discussed in detail by Tidball and Wehling-Henricks [188] , the loss of dystrophin and concomitant disintegration of its associated glycoprotein complex causes the disruption of free radicals production and this pathobiochemical alteration contributes in a major way to muscular degeneration. Possibly the disruption of cellular signaling mechanisms or a drastic shift in free radicals production is involved in cellular injury and resulting contractile weakness. The enzyme glutathione transferase is a crucial catalyst in glutathione-dependent phase 2 biotransformation reactions [189] . An increased concentration of both glutathione transferase and catalase was established to occur in the aged mdx heart as judged by proteomic analysis [142] .
These proteomic findings agree with elevated stress levels in dystrophinopathies and the idea that intensified protein oxidation by highly reactive free radical species causes cellular damage in both Duchenne patients and the mdx mouse [186, 188] . Anti-oxidant and biotransformation mechanisms appear to involve both glutathione transferase and catalase in muscular dystrophy [189] . Since the experimental elevation of catalase concentration was shown to improve mdx muscle functions [190] , the observed high expression of catalase in dystrophic fibres might represent a major protective mechanism to decrease cellular injury in muscular dystrophies. The proteomic identification of significant changes in the concentration of glutathione transferase and catalase might thus be useful to establish especially a heart-specific biomarker signature of muscular dystrophy-related changes [170] . The general status of enzymes involved in anti-oxidant responses and detoxification processes can then be used for evaluating levels of biotransformation in dystrophic or pharmacologically treated muscles.
MUSCLE DISEASE DIAGNOSTICS AND BIOMARKER DISCOVERY
Diagnosis of muscular dystrophy
Motor assessment plays an important role in the evaluation of disease status in dystrophic patients [191] [192] [193] [194] . In addition to the review of clinical history and physical examination, the conventional diagnosis of muscular dystrophies has heavily relied on electro-diagnostic testing, enzyme assays for the detection of muscle-related serum activity, the genetic evaluation of carriers and patients, the histological, histochemical and immunochemical evaluation of muscle biopsy specimens and the biochemical analyses of disease-related protein changes by gel electrophoresis and immunoblotting [71] . Since many of these routine tests are not very reliable, lack specificity with respect to differentiating between distinct neuromuscular pathologies and are invasive, there is great scope for the identification of superior diagnostic biomarkers of dystrophinopathies. A non-invasive alternative to muscle biopsy procedures is represented by magnetic resonance imaging and spectroscopy for the diagnosis and monitoring of disease progression, and potentially clinical outcome measures, in dystrophinopathies [195] [196] [197] . The clinical value of this imaging technique has been clearly demonstrated [198, 199] and a good correlation exists between skeletal muscle histology, as judged by the histochemical evaluation of muscle biopsies, and dystrophic changes observed by magnetic resonance imaging technology [200] . However, MRI scoring procedures require highly specialized equipment, are labor-intensive and often too expensive for routine screening programs. Hence, the development of a simple and cost-effective biomarker assay of a minimally invasive or non-invasive nature would overcome many of these financial and technical issues.
Proteomic biomarker discovery
With respect to developing dependable and non-invasive tests, large-scale mass spectrometric screening approaches are crucial for biomarker discovery in the area of muscular dystrophy research. This includes the development of reliable assay systems for the evaluation of disease initiation, pathological progression and the monitoring of therapeutic interventions. In addition, the proteomics-based discovery of diagnostically conclusive biomarker signatures of muscular diseases is crucial for an improved understanding of the molecular pathogenesis of individual disorders. Ideally, a panel of novel protein biomarkers of dystrophinopathies will be useful for initial disease diagnosis, prognostic evaluations and the continued assessment of therapy efficacies. The flowchart in Fig. 5 outlines the different classes of biomarkers needed for the proper monitoring of dystrophinopathies. The changed abundance of specific proteins, shifts in isoform expression patterns, modifications of protein-protein interactions, alterations in post-translational modifications, the degradation of distinct proteins and/or the appearance of musclederived proteins, protein fragments or peptides in body fluids might also provide new insights into pathological mechanism of dystrophinopathies. Once significant changes in protein concentration, protein constellation and/or subcellular localization have been established by biochemical and proteomic studies, dependable biomarkers can then be tested for their overall diagnostic, prognostic or therapeutic potential. In general, a protein biomarker should ideally be (i) easily assessable, (ii) very sensitive, (iii) diagnostically conclusive, (iv) highly specific for subtypes of distinct disorders, (v) informative in relation to individual stages of disease progression and (vi) exhibit physicochemical properties that make a particular protein species suitable for the establishment of a meaningful and cost-effective test system [64] . If the novel biomarker is an internal muscleassociated protein, it should preferably be located in a relatively restricted cellular compartment under healthy conditions, exhibit an appropriate degree of fibre type specificity within affected whole skeletal muscles and show significant difference in density levels, subcellular expression and/or molecular features in dystrophic specimens versus normal muscle samples. However, if the novel biomarker is a musclederived protein that has leaked or been released from contractile fibres, it should differ substantially between its intracellular and extracellular presence in undamaged versus dystrophic muscle. The degree of the disease-related occurrence of muscle markers in body fluids should ideally correlate with the onset, intensity and length of muscular damage. Both, internal biomarkers requiring invasive biopsy procedures or biofluid-associated muscle markers that can be obtained by minimally invasive or non-invasive methods, should be able to differentiate between acute pathological insults and chronic tissue damage.
Circulating biomarkers for monitoring general muscle damage
In the case of routine testing of Duchenne patients and the evaluation of carrier detection rates, historically the most frequently used serum enzyme activity has been creatine kinase [201] . In addition to serum creatine kinase [202] [203] [204] [205] [206] [207] [208] , other marker enzymes are represented by carbonic anhydrase [209] [210] [211] [212] , aldolase [213] , adenylate kinase [214] [215] [216] , lactate dehydrogenase [206, 207, 213] and pyruvate kinase [206, 208, 217, 218] . Assay systems were used with single enzyme activities or combinations of various muscle-derived enzymes in patient serum [206-208, 211, 213] . Besides the examining of disease progression in dystrophic children, screening approaches included fetal plasma [219, 220] and the blood analysis of newborns [204, 205, 221] , as well as a large number of investigations into the evaluation of carrier status [222] [223] [224] [225] [226] . The combined testing of several serum markers has shown the potential of improved screening efficiency, such as the usage of creatine kinase, myoglobin and hemopexin for identifying Duchenne muscular dystrophy carriers [227] . Besides serum and plasma, the testing of urine and saliva might also be useful for future diagnostic testing [228] [229] [230] [231] . Especially urine proteomics has great potential for discovering new disease indicators that are suitable for the establishment of simple and non-invasive assays [232] . The comparative profiling of the urine proteome has already identified several urinary biomarkers of physical activity [233] and muscle wasting during cancer cachexia [234] .
Muscle-derived proteins as specific markers of dystrophinopathies
In addition to the above outlined inherent complications of tissue proteomics, the future application of diagnostic or prognostic biomarkers associated with the muscle interior, as identified by proteomic profiling of cell mixtures, would require the undesirable usage of invasive methodology. Therefore proteomic screening programmes increasingly focus on the systematic analysis of suitable body fluids for differential analyses. In the future, the mining of the biofluid proteome promises to play a key role in diagnostic biomarker discovery in blood plasma, serum, urine and saliva [235] and the identification of new therapeutic targets [236] . The underlying objective of searching for biofluid-associated biomarkers is based on the assumption that firstly damaged tissues, that exist in close proximity to certain biological fluids, have a tendency to actively release or passively leak proteins into their external environment, and secondly that the overall range and/or density of shed proteins relates to the degree of cellular damage. This might lead to the identification of robust and unambiguous biomarkers of high clinical value [237] .
Since the identification and establishment of biofluid-based biomarkers is essential for improved diagnosis, enhanced approaches of risk stratification and the optimum management of pathological developments, recently international efforts have intensified and initiated the systematic screening of suitable body fluids for muscle-derived proteins. However, in contrast to the large number of proteomic studies described in above sections that have analysed muscle tissue extracts or subcellular fractions [63] , relatively few mass spectrometric investigations that focus on leaked or secreted proteins from dystrophic muscle tissues have been published [118] [119] [120] [121] [122] [123] . Serum and plasma, examples of distal biofluids, are composed of components originating from cells throughout the entire body, including various hormones, enzymes, glycoproteins, and growth factors. The choice of using serum versus plasma under specific experimental conditions is both acceptable. However, the HUPO committee and its research partners recommend plasma as the preferred specimen taken from blood, because it was found to have less ex vivo degradation and much less variability than the protease-rich process of clotting that is associated with serum processing [238, 239] . Many research groups take the opportunity to examine both serum and plasma in order to increase the overall coverage of the blood proteome in their investigations [86, 240] . Identification of disease-specific biomarkers is challenging in these samples given how substantially diluted biomolecules are in a matrix containing components derived from practically all tissues in the body [241] .
Using ProteoMiner™ beads to reduce the high dynamic range of the serum proteome from Duchenne muscular dystrophy, Becker muscular dystrophy, Bethlem myopathy, Myasthenia gravis and control groups, Martin et al. [122] found that fibronectin levels were significantly increased in Duchenne patients as compared to age-matched controls. In contrast, fibronectin levels in patients suffering from Becker muscular dystrophy, Bethlem myopathy or Myasthenia gravis were comparable to control levels. Fibronectin is a major component of the extracellular matrix with normal adult serum concentrations typically in the region of 220 g/ml. Tissue fibrosis, a characteristic of progressive X-linked muscular dystrophy, is generally considered to arise due to a failure of the normal wound response to cease, a process dependent on fibronectin in promoting cell adhesion and migration. The highly progressive elevation of fibronectin levels was also observed in longitudinal samples from Duchenne patients [122] . Besides fibronectin, interesting novel proteomic biomarker candidates of X-linked muscular dystrophy are the coagulation factor XIIIa and the matrix metalloproteinase MMP-9 [118] [119] [120] . It is important to note that no significant alterations of the serum concentration of collagen and laminin were found in Duchenne patients, showing that measuring these proteins is not useful for evaluating the extent of fibrosis in dystrophinopathies [242] .
Traditional biochemical analyses have previously established elevated serum levels of tissue inhibitors of metalloproteinase-1 and transforming growth factor TGF-beta1 in Duchenne patients [243] [244] [245] [246] . In addition, the proteomic screening of the secretome from mdx myotubes has demonstrated the release of a variety of vesicle-related proteins [123] . The mass spectrometric analysis revealed that lysosome-associated membrane protein 1 (LAMP1) containing vesicles comprise myosin light chain MLC1 and cytoskeletal proteins that are over-secreted in dystrophic myotubes [123] . Since skeletal muscles are now considered a secretory organ that releases a variety of myokines [247] , which are involved in signalling within the neuromuscular system and also other organs involved in bioenergetic provision, the detailed analysis of the muscle secretome promises opportunities both for diagnostic and therapeutic purposes [248] . The future screening of body liquids for muscle-derived peptides, protein fragments or intact proteins should be able to corroborate the already established proteomic findings and hopefully identify additional suitable biomarker candidates. An interesting new marker of general muscle damage is the protein Xin [249] . If Xin-like proteins would be identified as suitable markers of muscle damage severity in dystrophinopathies, in conjunction with released or leaked biomarkers, then the progressive nature of muscular dystrophy could be monitored in a more approachable fashion.
CONCLUSIONS
Biomarkers are measures of a biological state and are used as an indicator to determine and evaluate normal biological processes, pathogenic processes or pharmacological responses to therapeutic regimes. These biomarkers are produced either by the diseased tissue itself or by other neighbouring tissues in response to the presence of the disease or other associated conditions such as inflammation or the immune response. Mass spectrometry-based proteomic surveys of various muscles and body fluids, using both gel electrophoresis and/or liquid chromatography for large-scale protein separation, have identified a large number of potential biomarker candidates for the improved diagnostic evaluation of dystrophinopathies. The subcellular localization and disease-related concentration changes of major biomarker candidates of dystrophinopathies, as described in this review, are summarized in the diagrammatic presentation of Fig. 6 . Listed are the major categories of protein families that have been identified by proteomics-based screening approaches in conjunction with biochemical and cell biological verification analyses. Besides the members of the dystrophin-glycoprotein complex (dystrophin Dp427, dystroglycans, sarcoglycans, dystrobrevins, syntrophins, sarcospan), the figure includes proteins involved in (i) muscle contraction and the cytoskeleton (myosin heavy chains, myosin light chains, troponins, tropomyosin; auxiliary filament proteins, and the cytoskeletal proteins desmin, vimentin and tubulin), (ii) excitation-contraction coupling and ion homeostasis (calcium binding proteins, ion channels), (iii) extracellular matrix (collagen), (iv) cellular stress response (molecular chaperones cvHsp, ␣B-crystallin, Hsp70, Hsp90), (v) bioenergetic and metabolic pathways (aldolase, isocitrate dehydrogenase, adenylate kinase, creatine kinase) and (vi) muscle-derived proteins in body fluids (fibronectin, coagulation factor XIIIa, matrix metalloproteinase MMP-9, transforming growth factor TGF␤1). General serum markers of muscle damage are represented by creatine kinase, carbonic anhydrase and adenylate kinase, but these enzymes lack a high degree of specificity. The unchanged expression levels of the membrane cytoskeletal protein spectrin can be used as a loading control in comparative studies of muscle specimens. Laminin levels can be employed as an unchanged protein in dystrophic skeletal muscle preparations, but not for the analysis of cardiac tissues since its abundance is greatly reduced in dystrophindeficient cardiac tissues.
In analogy to the dystrophic grmd dog, in the future more detailed subproteomic studies might be possible due to the development of larger animal models of dystrophinopathies. Recently, the successful generation of a pig model of X-linked muscular dystrophy was reported using the targeted deletion of exon 52 in the dystrophin gene of male pig cells and the subsequent generation of severely dystrophic offspring by nuclear transfer [250] . The new model of progressive Duchenne muscular dystrophy exhibits increased serum creatine kinase levels, impaired mobility, contractile weakness and a drastically reduced life span of pigs due to respiratory impairment. Future proteomic studies of dystrophindeficient pigs may provide new insights into the hierarchy of physiological derangements in severe muscular dystrophy and provide sufficiently large amounts of contractile tissue for detailed subproteomic studies of the sarcolemma, mitochondria, sarcoplasmic reticulum, transverse tubules and nuclei. With respect to biomarker signatures on multiple biomolecular levels including ideally DNA, RNA, protein and metabolites, recent reports on musclespecific microRNAs and their suitability as minimally invasive serum biomarkers for Duchenne muscular dystrophy are encouraging [251] [252] [253] [254] [255] . The future combination of parallel tests that determine significant changes in muscle-associated proteomic biomarkers, muscle-derived proteins or protein fragments in body fluids, extracellular microRNAs and muscle metabolites appears to be the most appropriate approach for the comprehensive diagnostic, prognostic and therapeutic evaluation of X-linked muscular dystrophy.
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